Janus Henderson Group
NBIX icon

Janus Henderson Group’s Neurocrine Biosciences NBIX Stock Holding History

Janus Henderson Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.5M Buy
466,977
+7,801
+2% +$1.04M 0.03% 367
2025
Q4 		$65.1M Sell
459,176
-135,994
-23% -$19.7M 0.03% 368
2025
Q3 		$83.5M Sell
595,170
-180,900
-23% -$24.5M 0.04% 303
2025
Q2 		$97.5M Sell
776,070
-7,896
-1% -$906K 0.05% 266
2025
Q1 		$88.7M Sell
783,966
-10,152
-1% -$1.29M 0.05% 280
2024
Q4 		$108M Buy
794,118
+1,922
+0.2% +$238K 0.06% 267
2024
Q3 		$91.3M Sell
792,196
-179,007
-18% -$24.5M 0.05% 290
2024
Q2 		$134M Sell
971,203
-407,310
-30% -$55.9M 0.07% 228
2024
Q1 		$190M Sell
1,378,513
-172,854
-11% -$23.6M 0.1% 187
2023
Q4 		$204M Sell
1,551,367
-165,687
-10% -$19.1M 0.12% 182
2023
Q3 		$193M Sell
1,717,054
-191,790
-10% -$20.2M 0.13% 173
2023
Q2 		$180M Sell
1,908,844
-85,677
-4% -$8.37M 0.11% 184
2023
Q1 		$202M Sell
1,994,521
-421,117
-17% -$43.8M 0.13% 163
2022
Q4 		$289M Sell
2,415,638
-7,438,030
-75% -$871M 0.21% 123
2022
Q3 		$1.05B Buy
9,853,668
+4,639,934
+89% +$471M 0.39% 58
2022
Q2 		$508M Sell
5,213,734
-1,096,029
-17% -$101M 0.35% 68
2022
Q1 		$592M Sell
6,309,763
-1,136,076
-15% -$96.3M 0.29% 79
2021
Q4 		$634M Sell
7,445,839
-1,540,472
-17% -$142M 0.26% 86
2021
Q3 		$862M Buy
8,986,311
+34,237
+0.4% +$3.23M 0.38% 57
2021
Q2 		$871M Sell
8,952,074
-279,215
-3% -$26.8M 0.37% 58
2021
Q1 		$898M Buy
9,231,289
+70,148
+0.8% +$7.36M 0.41% 52
2020
Q4 		$878M Buy
9,161,141
+2,612,748
+40% +$252M 0.41% 56
2020
Q3 		$630M Buy
6,548,393
+54,202
+0.8% +$6.27M 0.33% 66
2020
Q2 		$792M Sell
6,494,191
-1,135,008
-15% -$125M 0.44% 42
2020
Q1 		$660M Buy
7,629,199
+255,687
+3% +$25M 0.45% 45
2019
Q4 		$793M Sell
7,373,512
-1,130,024
-13% -$118M 0.41% 53
2019
Q3 		$766M Sell
8,503,536
-848,704
-9% -$79.3M 0.42% 56
2019
Q2 		$790M Buy
9,352,240
+540,279
+6% +$44.4M 0.43% 46
2019
Q1 		$776M Buy
8,811,961
+4,547
+0.1% +$380K 0.43% 46
2018
Q4 		$629M Buy
8,807,414
+1,644,949
+23% +$158M 0.4% 51
2018
Q3 		$881M Sell
7,162,465
-252,396
-3% -$28.6M 0.47% 36
2018
Q2 		$728M Sell
7,414,861
-49,133
-0.7% -$4.4M 0.42% 46
2018
Q1 		$619M Buy
7,463,994
+1,691,883
+29% +$143M 0.36% 61
2017
Q4 		$448M Buy
5,772,111
+264,348
+5% +$18M 0.27% 96
2017
Q3 		$338M Buy
5,507,763
+140,639
+3% +$7.42M 0.22% 132
2017
Q2 		$247M Buy
+5,367,124
New +$260M 0.17% 166

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's NBIX Position: Q1 2026 in Review

Janus Henderson Group increased its Neurocrine Biosciences (NBIX) stake by 1.7% in Q1 2026, buying an estimated $1.04M and bringing the position to 466,977 shares worth $61.5M. The position accounts for 0.03% of the portfolio, ranked #367.

Janus Henderson Group first reported a position in NBIX in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.05B in Q3 2022. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Janus Henderson Group held 466,977 shares of Neurocrine Biosciences worth $61.5M as of Q1 2026.
  • Janus Henderson Group bought 7,801 Neurocrine Biosciences shares in Q1 2026, an estimated $1.04M.
  • Neurocrine Biosciences made up 0.03% of Janus Henderson Group's portfolio in Q1 2026, its #367 holding.
  • Janus Henderson Group first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 36 quarters since.
  • Janus Henderson Group's Neurocrine Biosciences position peaked at $1.05B in Q3 2022.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.